Kexing Biopharm announces that the First Inspection Office of the Jinan Taxation Bureau of the State Administration of Taxation has conducted a tax inspection on the company's tax-related situation from January 1, 2021 to December 31, 2022. The company is required to pay a total of 21.3111 million yuan, including 15.4877 million yuan of corporate income tax and 5.8234 million yuan of late payment fees (as of the actual payment date). As of the date of this announcement, the company has paid the above-mentioned tax and surcharges as required, and the competent tax department has not imposed any penalties on this matter. The payment of the above-mentioned tax and surcharges by the company will be included in the current year's profit and loss in 2024, and it is expected to affect the net income attributable to shareholders of the listed company in 2024 by approximately 21.3111 million yuan.